<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
placeholder

Lunning and Kamdar Debate the Role of Pola-R-CHP in Treatment-Naïve DLBCL

minute read

Written by OncLive on July 24, 2023

Drs Lunning and Kamdar spotlight the design of the POLARIX trial, the ways in which its results have changed their practice when treating patients with DLBCL, and the importance of further research investigating the molecular heterogeneity of this disease to determine potential causes of early relapse with pola-R-CHP.

Topics: Press Coverage

Comments

Related Stories